Dawson James Securities initiated coverage of Genprex (NASDAQ:GNPX) with a “buy” rating and $3 price target. The stock closed at $1.34 on Jan. 27. Genprex is a clinical-stage gene therapy company pioneering the...
The FDA granted fast track designation for Genprex’s (NASDAQ:GNPX) Oncoprex immunogene therapy in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth...